Clinical trials: Adenocarcinoma of the Prostate Stage III
Gastrointestinal Complications, Prostate Cancer
RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Androgens can cause the growth of prostate cancer cells.
- Conditions
- Gastrointestinal Complications, Prostate Cancer, Sexual Dysfunction, Urinary Complications
- Trial name
- NCT00541047
- Testing
- bicalutamide, goserelin acetate, leuprolide acetate
- Where
- 58 sites in Canada, United Kingdom
- Volunteers
- 4,236 people
- Sponsor
- University College, London
Prostate Cancer
SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer
RATIONALE: SB939 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well SB939 works in treating patients with recurrent or metastatic prostate…
- Trial name
- NCT01075308
- Testing
- HDAC inhibitor SB939
- Where
- 7 sites in Canada
- Volunteers
- 32 people
- Sponsor
- NCIC Clinical Trials Group
Adenocarcinoma of the Prostate, Stage I Prostate Cancer
Intensity-Modulated External Beam Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Specialized radiation therapy, such as intensity-modulated radiation therapy, that delivers a high dose of radiation directly…
- Conditions
- Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer
- Trial name
- NCT01117935
- Testing
- intensity modulated external beam radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Virginia Commonwealth University
Prostate Cancer
Mitoxantrone Following Surgery in Treating Patients With Prostate Cancer at High Risk for Recurrence
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy after surgery may kill more tumor cells.
- Trial name
- NCT00003858
- Testing
- mitoxantrone hydrochloride
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
Atrasentan in Treating Patients With Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase III trial to determine the effectiveness of atrasentan in treating patients who have prostate…
- Trial name
- NCT00046943
- Testing
- atrasentan hydrochloride
- Where
- United States
- Sponsor
- Abbott
Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8
Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery
This phase II trial studies how well enteric-coated (EC) aspirin and rintatolimod with or without interferon-alpha 2b work in treating patients with prostate cancer before surgery.
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8
- Trial name
- NCT03899987
- Testing
- EC Aspirin, Radical Prostatectomy, Recombinant Interferon Alfa-2b
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Roswell Park Cancer Institute
Prostate Cancer
Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as ketoconazole, may stop the adrenal glands from making androgens.
- Trial name
- NCT00460031
- Testing
- ketoconazole, lenalidomide, therapeutic hydrocortisone
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Case Comprehensive Cancer Center
Biochemically Recurrent Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma
An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer
This trial studies how well 68Ga-PSMA-11 PET scan works in imaging patients with prostate cancer. Diagnostic procedures, such as 68Ga-PSMA-11 PET may find and diagnose prostate cancer and improve monitoring of treatment response.
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8
- Trial name
- NCT04777071
- Testing
- Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- University of Washington
Prostate Cancer
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Hormones can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00005044
- Testing
- Casodex, Eulexin, LHRH agonist
- Where
- 261 sites in United States, Canada
- Volunteers
- 1,579 people
- Sponsor
- Radiation Therapy Oncology Group
Cancer
Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients
RATIONALE: Palliative care may help patients with advanced cancer live more comfortably. PURPOSE: This randomized clinical trial is studying an early intervention palliative care program to see how well it works compared to a…
- Trial name
- NCT00253383
- Testing
- counseling intervention, educational intervention, psychosocial assessment and care
- Where
- 2 sites in United States
- Volunteers
- 329 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Prostate Cancer
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
Current therapies for Stage III or Stage IV Prostate Cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Stage III or…
- Trial name
- NCT00003516
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Burzynski Research Institute
Prostate Cancer
Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as triptorelin, may lessen the amount of androgens made by the body. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00667069
- Testing
- triptorelin, adjuvant therapy, 3-dimensional conformal radiation therapy
- Where
- 17 sites in France
- Volunteers
- 424 people
- Sponsor
- UNICANCER
Prostate Cancer
Combination Hormone Therapy Followed by Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using triptorelin and flutamide may fight cancer by reducing the production of androgens.
- Trial name
- NCT00003734
- Testing
- flutamide, triptorelin, radiation therapy
- Where
- 12 sites in Ireland, United Kingdom
- Volunteers
- 276 people
- Sponsor
- St. Luke's Hospital, Ireland
Adenocarcinoma of the Prostate, Stage III Prostate Cancer
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
RATIONALE: Antineoplastons are naturally occurring substances that may also be made in the laboratory. Antineoplastons may inhibit the growth of cancer cells.
- Conditions
- Adenocarcinoma of the Prostate, Stage III Prostate Cancer, Stage IV Prostate Cancer, Recurrent Prostate Cancer
- Trial name
- NCT00003517
- Testing
- antineoplaston A10, antineoplaston AS2-1, bicalutamide
- Where
- United States
- Sponsor
- Burzynski Research Institute
Prostate Cancer
Vitamin D in Treating Patients With Prostate Cancer
RATIONALE: Vitamin D may be effective in treating patients with prostate cancer. PURPOSE: This randomized phase II trial is studying how well 4 different doses of vitamin D works in treating patients with prostate cancer.
- Trial name
- NCT00524680
- Testing
- cholecalciferol
- Where
- United States
- Volunteers
- 148 people
- Sponsor
- Roswell Park Cancer Institute
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
This randomized phase III trial is studying docetaxel, prednisone, and bevacizumab to see how well they work compared to docetaxel and prednisone in treating patients with prostate cancer that did not respond to hormone therapy.
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT00110214
- Testing
- docetaxel, prednisone, bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 1,050 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer, Adenocarcinoma of the Prostate
Study of Histrelin Subdermal Implant in Patients With Prostate Cancer
This trial was an open-label, multi-national, randomized, parallel treatment, active-control multicenter study in adult males with documented metastatic prostate cancer disease who were judged to be candidates for hormone therapy.
- Trial name
- NCT01394263
- Testing
- Histrelin hydrogel implant, Zoladex goserelin implant
- Volunteers
- 59 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Prostate Cancer
Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00255606
- Testing
- docetaxel, prednisone
- Where
- 19 sites in Finland, Ireland and 1 more
- Volunteers
- 360 people
- Sponsor
- Tampere University
Prostate Cancer
Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
RATIONALE: Radiation therapy uses high energy x-rays to damage tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of conventional radiation therapy with high-dose radiation therapy in treating men with…
- Trial name
- NCT00002703
- Testing
- high-LET heavy ion therapy, low-LET photon therapy
- Where
- 2 sites in United States
- Volunteers
- 390 people
- Sponsor
- Proton Radiation Oncology Group
Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
This phase I trial is studying the side effects and best dose of alvespimycin hydrochloride in treating patients with metastatic or unresectable solid tumors.
- Conditions
- Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Breast Cancer
- Trial name
- NCT00089362
- Testing
- alvespimycin hydrochloride, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)